Your cart is empty!
View Cart Checkout
Cart subtotal: 0.00 €

Studies on Longvida®

 

High Bioavailability

An innovative formulation with an optimal bioavailability: Longvida

In the 1990s, a group of top neuroscientists at the UCLA School of Medicine, led by Dr. Sally Frautschy Ph.D. and Dr. Greg Cole Ph.D. began their quest to find a safe, effective, and affordable way to support cognitive functions.

After ten years, nearly 200 curcumin-based formulas, and endless trial and error, curcumin’s bioavailability issue has been solved, with the Optimized Curcuma’s patented Solid Lipid Curcumin Particle Technology (SLCP™).

The secret of Optim Curcuma lies in the Longvida Solid-Lipid Curcumin Particle (SLCP™) patented process which consists of encapsulating the curcumin to enhance its dissolution at a precise point in the gut and thus deliver it into both plasma and red blood cells as free curcumin, the biological active form of curcumin (DiSilvestro 2012).

Longvida SLCP Curcumin turmeric EN

Clinical studies performed on this unique formulation demonstrated it to be safe with daily intakes as high as 4g (10 capsules).

Bioavailability studies in humans

Gota et al. (2010) investigated the pharmacokinetics of Longvida® preparation in adult human subjects. They performed a crossover, double-blind analysis, where six healthy men were given Longvida® SLCP curcumin preparation and 95% curcuminoids formula (containing > 60% curcumin) in capsule form in a single oral dose of 650 mg (containing 130-195 mg of curcumin from Longvida® preparation and >390 mg of curcumin from 95% curcuminoids extract). Blood samples were collected before dosing and from 1 to 12 hours after administration and plasma samples (as free form curcumin) were analyzed by HPLC. Figure 1 reports the mean free plasma curcumin concentration profile for the Longvida preparation.

Gota Graph.001

Figure 1 Mean Free Plasma Curcumin Concentration-Time Profile of healthy human subjects (N=6) from Gota et al (2010).

 

In healthy subjects, the mean peak concentration of curcumin achieved from dosing 650 mg of Longvida® preparation was 22.43 ng/mL, whereas plasma curcumin from dosing an equal quantity of unformulated 95% curcuminoids extract was not detected (<1 ng/ml).

Table 1 reports the maximum concentrations (Cmax) of curcumin in the plasma after dosing with either 650 mg of Longvida® preparation- minimum 130mg Curcumin – or 650 mg of a standard 95% curcuminoids extract – 390mg curcumin – (Gota et al 2010). The longvida® preparation was reported to be at least 65 times more available than standard 95% curcuminoids extracts.

 

Table 1: Curcumin Cmax of Longvida versus standard 95% Curcuminoid Extract (Gota et al. 2010)

Human Plasma Curcumin
Cmax (ng/ml)

650mg Longvida®  SLCP curcumin preparation
with 130 mg curcumin min.

22.4

650 mg 95% Curcuminoids extract
with 390 mg Curcumin min.

<1

 

 

 

Is the dosage of Optim Curcuma effective ?

A recent clinical trial led by a group of researcher from the Ohio State University – USA (DiSilvestro 2012) analyzed various biological markers among healthy middle-aged people (40 to 60 years old) taking either placebo (N=19) or 400 mg of Longvida® preparation (N=19) for 30 days.

They reported that Longvida® SLCP curcumin preparation significantly reduced circulating amyloid-beta peptides, reduced vascular adhesion molecules in the blood (sICAM-1); reduced blood lipids (plasma triglycerides); reduced enzymes for physiological and emotional stress (salivary amylase); and significantly increased the antioxidant status by 24% and the endogenous antioxidant defense (catalase) by 72%; the vasodilator activity (plasma nitric oxide) by 37% and decreased liver enzymes levels (ALT: Alamine Amino Transferase) by 11%.

 Chart DiSilvestro .001

Figure 2 Significative Changes of Biological Markers versus Placebo (p<0.05) after 4 weeks of 400mg Longvida® preparation intake (DiSilvestro 2012) 

 

Interview with Dr. Robert Di Silvestro from the Ohio State University:

 

 

Memory and Cognitive functions

A group of researchers from the University of Swinburne in Melbourne, Australia, recently published the results of a randomised, double-blind, placebo-controlled study (Cox et al 2014).

During 4 weeks, 60 participants from 60 to 85 year old took either:

  • either 400 mg/day of either the patented LongVida SLCP curcumin complex of OptimCurcuma (80 mg curcumin)
  • or 400mg of placebo.

The authors reported that the curcumin supplementation significantly improved both acute and chronic cognitive functions, particularly working memory tasks, general fatigue, and calmness, compared with placebo.

Muscle recovery  

A study from the University of  North Texas published in Biochimica et Biophysica Acta Clinica suggests that the formulation Longvida of Optim Curcuma reduces the increases of inflammation and improved muscle recovery after a leg press exercise, compared to a placebo group. (McFarlin 2016)

28 young participants (average 20 years old) were randomly assigned to consume either 400 mg of Longvida SLCP curcumin – the formulation of OptimCurcuma – or a placebo (rice flour) for 2 days before and 4 days after the Exercise-Induced Muscle Damage. Blood samples were collected before exercise and at day 1,2,3 and 4. The muscle damage biomarker (Creatine Kinase) and the inflammatory biomarkers (cytokines: TNF-α, IL-6, IL-8, and IL-10) were measured.

Among participants in the curcumin group, researchers observed significantly smaller increases in Creatine Kinase (–48%), TNF-α (–25%), and IL-8 (–21%) following exercise compared to the placebo group. No significant decrease was found for IL-6, IL-10, or quadriceps muscle soreness.

The findings demonstrated that a daily intake of 1 capsule of the formulation of Optim Curcuma – reduced biological inflammation during recovery after the Exercise-Induced Muscle Damage (EIMD) and this may translate to faster recovery.

A natural solution for tendinitis

 

 

References

Anand P, Kunnumakkara AB, Newman RA, Aggarwal BB. Bioavailability of curcumin: problems and promises. Mol Pharm. 2007 Nov-Dec;4(6):807-18. http://www.ncbi.nlm.nih.gov/pubmed/17999464

Begum AN, Jones MR, Lim GP, Morihara T, Kim P, Heath DD, Rock CL, Pruitt MA, Yang F, Hudspeth B, Hu S, Faull KF, Teter B, Cole GM, Frautschy SA. Curcumin structure-function, bioavailability, and efficacy in models of neuroinflammation and Alzheimer’s disease. J Pharmacol Exp Ther. 2008 Jul;326(1):196-208 http://www.ncbi.nlm.nih.gov/pubmed/18417733

Cox KH, Pipingas A, Scholey AB. Investigation of the effects of solid lipid curcumin on cognition and mood in a healthy older population. J Psychopharmacol. 2014 Oct 2 http://www.ncbi.nlm.nih.gov/pubmed/25277322

Dadhaniya P, Patel C, Muchhara J, Bhadja N, Mathuria N, Vachhani K, Soni MG. Safety assessment of a solid lipid curcumin particle preparation: acute and subchronic toxicity studies. Food Chem Toxicol. 2011 Aug;49(8):1834-42 http://www.ncbi.nlm.nih.gov/pubmed/21571027

DiSilvestro RA, Joseph E, Zhao S, Bomser J. Diverse effects of a low dose supplement of lipidated curcumin in healthy middle aged people. Nutr J. 2012 Sep 26;11:79 http://www.ncbi.nlm.nih.gov/pubmed/23013352

European Patent: EP 1993365B1” Bioavailable curcuminoid formulations for treating alzheimer’s disease and other age-related disorders” http://www.google.com/patents/EP1993365A2?cl=en

Frautschy, SF “Improving bioavailability of curcumin by solid lipid particle for treatment of Alzheimer’s (AD)” at the 38th Annual Meeting of the Society of Neuroscience ,
Washington DC, November 15, 2008

Gota VS, Maru GB, Soni TG, Gandhi TR, Kochar N, Agarwal MG. Safety and pharmacokinetics of a solid lipid curcumin particle formulation in osteosarcoma patients and healthy volunteers. J Agric Food Chem. 2010 Feb 24;58(4):2095-9 http://www.ncbi.nlm.nih.gov/pubmed/20092313

Jurenka JS. Anti-inflammatory properties of curcumin, a major constituent of Curcuma longa: a review of preclinical and clinical research. Altern Med Rev. 2009 Jun;14(2):141-53 http://www.ncbi.nlm.nih.gov/pubmed/19594223

McFarlin B.K., A.S. Venable, A.L. Henning, J.N Best Sampson, K. Pennel, J.L. Vingren, D.W. Hill; Reduced inflammatory and muscle damage biomarkers following oral supplementation with bioavailable curcumin; BBA Clinical, Volume 5, June 2016, Pages 72–78.

Nahar PP, Slitt AL, Seeram NP. Anti-Inflammatory Effects of Novel Standardized Solid Lipid Curcumin Formulations. J Med Food. 2014 Dec 9 – http://www.ncbi.nlm.nih.gov/pubmed/25490740

Volak LP, Hanley MJ, Masse G, Hazarika S, Harmatz JS, Badmaev V, Majeed M, Greenblatt DJ, Court MH. Effect of a herbal extract containing curcumin and piperine on midazolam, flurbiprofen and paracetamol (acetaminophen) pharmacokinetics in healthy volunteers. Br J Clin Pharmacol. 2013 Feb;75(2):450-62
http://www.ncbi.nlm.nih.gov/pubmed/22725836

WHO Monographs on Selected Medicinal Plants – Volume 1;
http://apps.who.int/medicinedocs/en/d/Js2200e/14.html#Js2200e.14